NEW YORK, July 24 - Cepheid announced on Tuesday second-quarter revenues of $2 million, compared to $1.2 million from the year ago period. For the six months ended June 30, Cepheid's revenues increased to $5.4 million from $2.1 million.

The maker of equipment for rapidly preparing and analyzing DNA attributed the increase to the extension of sales of its Smart Cycler DNA testing system. During this latest quarter, Cepheid sold the Smart Cycler within North America, Europe, and Asia; in the year ago period, it had access to only the US market.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.